Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference

Core Insights - Oculis Holding AG is participating in the H.C Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025, highlighting its focus on ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs [1][4] Company Overview - Oculis is a global biopharmaceutical company with a focus on innovations for ophthalmic and neuro-ophthalmic conditions [4] - The company has a differentiated late-stage clinical pipeline that includes three core product candidates: - OCS-01, an eye drop in pivotal registration studies aimed at becoming the first non-invasive topical treatment for diabetic macular edema - Privosegtor (OCS-05), a neuroprotective candidate in Phase 2 for acute optic neuritis, with potential applications in various neuro-ophthalmic and neurological diseases - Licaminlimab (OCS-02), a novel topical anti-TNFα in Phase 2, developed with a genotype-based approach for personalized medicine in dry eye disease [4] Upcoming Events - Sylvia Cheung, CFO of Oculis, will present a corporate update available for replay via webcast at 7:00am ET - Snehal Shah, President of R&D, will participate in a live panel discussion on Pivotal-Stage Assets for Retinal Disorders from 11:00am to 12:00pm ET, which will also be available for replay [5]